<li>acarbose<p>nortriptyline increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>amobarbital<p>amobarbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>atropine<p>nortriptyline increases levels of atropine by unknown mechanism. Minor/Significance Unknown.</p></li><li>atropine iv/im<p>nortriptyline increases levels of atropine iv/im by unknown mechanism. Minor/Significance Unknown.</p></li><li>bazedoxifene/conjugated estrogens<p>bazedoxifene/conjugated estrogens, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>brimonidine<p>nortriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>butabarbital<p>butabarbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>butalbital<p>butalbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>carbamazepine<p>carbamazepine decreases levels of nortriptyline by increasing metabolism. Minor/Significance Unknown.</p></li><li>chlorpromazine<p>nortriptyline, chlorpromazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, chlorpromazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>chlorpropamide<p>nortriptyline increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>conjugated estrogens<p>conjugated estrogens, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>conjugated estrogens, vaginal<p>conjugated estrogens, vaginal, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>desflurane<p>desflurane, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of nortriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>diltiazem<p>diltiazem increases levels of nortriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>enflurane<p>enflurane, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>estradiol<p>estradiol, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>estrogens conjugated synthetic<p>estrogens conjugated synthetic, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>estrogens esterified<p>estrogens esterified, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.</p></li><li>estropipate<p>estropipate, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>ethinylestradiol<p>ethinylestradiol, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.</p></li><li>etomidate<p>etomidate, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>eucalyptus<p>nortriptyline and eucalyptus both increase  sedation. Minor/Significance Unknown.</p></li><li>fluphenazine<p>nortriptyline, fluphenazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, fluphenazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>glimepiride<p>nortriptyline increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>glipizide<p>nortriptyline increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>gliquidone<p>nortriptyline increases effects of gliquidone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>glyburide<p>nortriptyline increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>hexobarbital<p>hexobarbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>hydroxyprogesterone caproate<p>hydroxyprogesterone caproate, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>insulin aspart<p>nortriptyline increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin detemir<p>nortriptyline increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin glargine<p>nortriptyline increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin glulisine<p>nortriptyline increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin lispro<p>nortriptyline increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin nph<p>nortriptyline increases effects of insulin nph by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>insulin regular human<p>nortriptyline increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>isoproterenol<p>isoproterenol, nortriptyline. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.</p></li><li>ketamine<p>ketamine, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>lithium<p>lithium, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Risk of neurotoxicity in geriatric pts.  Multiple mechanisms involved.</p></li><li>mephobarbital<p>mephobarbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>mestranol<p>mestranol, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>metformin<p>nortriptyline increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>methylphenidate<p>methylphenidate increases effects of nortriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>miglitol<p>nortriptyline increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>nateglinide<p>nortriptyline increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>panax ginseng<p>panax ginseng increases effects of nortriptyline by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>pentobarbital<p>pentobarbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>perphenazine<p>nortriptyline, perphenazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, perphenazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>phenobarbital<p>phenobarbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>pioglitazone<p>nortriptyline increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of nortriptyline by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>primidone<p>primidone, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>prochlorperazine<p>nortriptyline, prochlorperazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, prochlorperazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>progesterone micronized<p>progesterone micronized, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.</p></li><li>promazine<p>nortriptyline, promazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, promazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>promethazine<p>nortriptyline, promethazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, promethazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>propofol<p>propofol, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>repaglinide<p>nortriptyline increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>rifampin<p>rifampin decreases levels of nortriptyline by increasing metabolism. Minor/Significance Unknown.</p></li><li>rosiglitazone<p>nortriptyline increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>sage<p>nortriptyline and sage both increase  sedation. Minor/Significance Unknown.</p></li><li>saxagliptin<p>nortriptyline increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>secobarbital<p>secobarbital, nortriptyline. Other (see comment). Minor/Significance Unknown. 
Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.</p></li><li>sevoflurane<p>sevoflurane, nortriptyline. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.</p></li><li>sitagliptin<p>nortriptyline increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>sulfamethoxazole<p>sulfamethoxazole decreases levels of nortriptyline by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>thioridazine<p>nortriptyline, thioridazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, thioridazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>tolazamide<p>nortriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>tolbutamide<p>nortriptyline increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>trifluoperazine<p>nortriptyline, trifluoperazine.
Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.<span><br><br></span>nortriptyline, trifluoperazine.
Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.</p></li><li>troglitazone<p>nortriptyline increases effects of troglitazone by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>vasopressin<p>nortriptyline increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>verapamil<p>verapamil increases levels of nortriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>vildagliptin<p>nortriptyline increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>zolpidem<p>zolpidem, nortriptyline.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.</p></li>